The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression. As part of the study design, a subset of patients will initially undergo dynamic PET/CT imaging to evaluate the safety profile and pharmacokinetic distribution of the radiotracer in vivo. Subsequently, static PET/CT imaging will be performed on additional patients to assess the diagnostic effectiveness of 68Ga-DOTA-dPNE. Imaging results will be correlated with relevant clinical indicators to evaluate the potential of this tracer in diagnosing breast cancer, guiding therapeutic decisions, and predicting responses to targeted therapies.
None
None
Single group
68GA-DOTA-dPNE
DrugPatients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
The evaluation of diagnostic performance of 68Ga-DOTA-dPNE PET in breast cancer
Patients with histologically proven breast cancer will be prospectively recruited in this study. They will receive 68Ga-DOTA-dPNE and 18F-FDG. The detection rates of lesions, bones and lymph nodes (visual) were compared.
Map coordinates are unavailable for these locations. Locations are shown below instead.
ChinaClick on the lead sponsor to view all of their trials.
